Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects With Hematologic Malignancies

NCT01090414 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01090414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01090414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects With Hematologic Malignancies
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Terminated
Start date
March 22, 2010
Completion date
June 18, 2018
Enrollment
202 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, lymphoma, non-hodgkin